|
DE19718012C1
(de)
*
|
1997-04-29 |
1998-10-08 |
Jenapharm Gmbh |
Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
|
|
US6559158B1
(en)
|
1997-11-03 |
2003-05-06 |
Ur Labs, Inc. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
|
|
US20030158220A1
(en)
*
|
1997-11-03 |
2003-08-21 |
Foss Joseph F. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
|
|
US6274591B1
(en)
|
1997-11-03 |
2001-08-14 |
Joseph F. Foss |
Use of methylnaltrexone and related compounds
|
|
CA2314893C
(en)
|
1997-12-22 |
2005-09-13 |
Euro-Celtique, S.A. |
Opioid agonist/antagonist combinations
|
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
|
UA53774C2
(uk)
|
1997-12-22 |
2003-02-17 |
Еро-Селтік, С.А. |
Спосіб запобігання зловживанню лікарськими формами, що містять опіоїди
|
|
DE19853487A1
(de)
*
|
1998-11-19 |
2000-05-25 |
Fumapharm Ag Muri |
Verwendung von Dialkylfumaraten
|
|
US6451806B2
(en)
|
1999-09-29 |
2002-09-17 |
Adolor Corporation |
Methods and compositions involving opioids and antagonists thereof
|
|
US6469030B2
(en)
|
1999-11-29 |
2002-10-22 |
Adolor Corporation |
Methods for the treatment and prevention of ileus
|
|
US6716449B2
(en)
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
|
AU776904B2
(en)
*
|
2000-02-08 |
2004-09-23 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
|
EP1389092B1
(en)
*
|
2001-05-11 |
2006-11-15 |
Endo Pharmaceuticals Inc. |
Abuse-resistant opioid dosage form
|
|
ATE493130T1
(de)
|
2001-05-11 |
2011-01-15 |
Endo Pharmaceuticals Inc |
Opioid enthaltende arzneiform gegen missbrauch
|
|
ATE446751T1
(de)
*
|
2001-06-05 |
2009-11-15 |
Univ Chicago |
Verwendung von methylnaltrexon zur behandlung von immunsuppression
|
|
PT1416842E
(pt)
|
2001-07-18 |
2009-03-31 |
Euro Celtique Sa |
Composições farmacêuticas de oxicodona e naloxona
|
|
RU2004106619A
(ru)
|
2001-08-06 |
2005-07-10 |
Эро-Селтик С.А. (Lu) |
Композиции опиоидного агониста, содержащие высвобождаемый и изолированный антагонист
|
|
WO2003013433A2
(en)
|
2001-08-06 |
2003-02-20 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
|
LT1436012T
(lt)
|
2001-10-18 |
2018-04-10 |
Nektar Therapeutics |
Opioidų antagonistų polimerų konjugatai
|
|
DE17154462T1
(de)
|
2002-04-05 |
2019-12-19 |
Euro-Celtique S.A. |
Matrix für nachhaltige, invariante und unabhängige freisetzung von wirkstoffverbindungen
|
|
WO2004026283A1
(en)
|
2002-09-20 |
2004-04-01 |
Alpharma, Inc. |
Sequestering subunit and related compositions and metohds
|
|
MXPA05010821A
(es)
*
|
2003-04-08 |
2006-03-30 |
Progenics Pharm Inc |
Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico.
|
|
CN104383542B
(zh)
*
|
2003-04-08 |
2017-09-26 |
普罗热尼奇制药公司 |
包含甲基纳曲酮的药物配方
|
|
WO2004091622A1
(en)
*
|
2003-04-08 |
2004-10-28 |
Progenics Pharmaceuticals, Inc. |
The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
|
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
|
AU2013203378B2
(en)
*
|
2003-04-08 |
2016-09-15 |
Progenics Pharmaceuticals, Inc. |
Pharmaceutical formulations containing methylnaltrexone
|
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
|
US20060182692A1
(en)
*
|
2003-12-16 |
2006-08-17 |
Fishburn C S |
Chemically modified small molecules
|
|
NZ594834A
(en)
*
|
2003-12-16 |
2013-03-28 |
Nektar Therapeutics |
Method of preparing PEGylated protein molecules
|
|
EP1604666A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
|
EP1604667A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the restless leg syndrome
|
|
EP1845989A1
(en)
*
|
2005-01-20 |
2007-10-24 |
Progenics Pharmaceuticals, Inc. |
Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
|
|
AP2274A
(en)
*
|
2005-01-28 |
2011-08-19 |
Euro Celtiques Sa |
Alcohol resistant dosage forms.
|
|
EP1695700A1
(en)
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Dosage form containing oxycodone and naloxone
|
|
EP1702558A1
(en)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
|
CN101171010B
(zh)
|
2005-03-07 |
2014-09-17 |
芝加哥大学 |
阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
|
|
US9662325B2
(en)
|
2005-03-07 |
2017-05-30 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
|
US8524731B2
(en)
|
2005-03-07 |
2013-09-03 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
|
US8518962B2
(en)
|
2005-03-07 |
2013-08-27 |
The University Of Chicago |
Use of opioid antagonists
|
|
AR057325A1
(es)
|
2005-05-25 |
2007-11-28 |
Progenics Pharm Inc |
Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
|
|
AR057035A1
(es)
|
2005-05-25 |
2007-11-14 |
Progenics Pharm Inc |
SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
|
|
US20080194611A1
(en)
*
|
2005-06-03 |
2008-08-14 |
Alverdy John C |
Modulation of Cell Barrier Dysfunction
|
|
DE102006006532B4
(de)
*
|
2006-02-10 |
2007-11-08 |
Biogenerics Pharma Gmbh |
Pharmazeutische Zubereitung
|
|
KR20140079441A
(ko)
|
2006-06-19 |
2014-06-26 |
알파마 파머슈티컬스 엘엘씨 |
약제학적 조성물
|
|
TWI489984B
(zh)
|
2006-08-04 |
2015-07-01 |
Wyeth Corp |
用於非經腸道傳輸化合物之配方及其用途
|
|
US20080139654A1
(en)
*
|
2006-12-09 |
2008-06-12 |
Eric Mott Soderling |
Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
|
|
DK2139890T3
(da)
|
2007-03-29 |
2014-08-25 |
Wyeth Llc |
Perifere opioidreceptor-antagonister og anvendelser deraf
|
|
WO2008121352A2
(en)
|
2007-03-29 |
2008-10-09 |
Progenics Pharmaceuticals, Inc. |
Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof
|
|
PL2137191T3
(pl)
|
2007-03-29 |
2016-12-30 |
|
Antagoniści obwodowego receptora opioidowego i ich zastosowania
|
|
US8748448B2
(en)
|
2007-10-18 |
2014-06-10 |
Aiko Biotechnology |
Combination analgesic employing opioid agonist and neutral antagonist
|
|
US8883817B2
(en)
*
|
2007-10-18 |
2014-11-11 |
Aiko Biotechnology |
Combination analgesic employing opioid and neutral antagonist
|
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
|
KR101581480B1
(ko)
|
2008-02-06 |
2015-12-30 |
프로제닉스 파머슈티컬스, 인코포레이티드 |
(ｒ),(ｒ)-2,2'-비스-메틸날트렉손의 제조법 및 용도
|
|
EP2278966B1
(en)
|
2008-03-21 |
2019-10-09 |
The University of Chicago |
Treatment with opioid antagonists and mtor inhibitors
|
|
EP2306829B1
(en)
*
|
2008-07-01 |
2017-01-04 |
University of Chicago |
Particles containing a peripheral opioid receptor antagonist
|
|
CA2676881C
(en)
|
2008-09-30 |
2017-04-25 |
Wyeth |
Peripheral opioid receptor antagonists and uses thereof
|
|
ME03298B
(me)
|
2009-03-10 |
2019-07-20 |
Euro Celtique Sa |
Farmaceutske kombinacije sa trenutnim oslobađanjem које obuhvataju oksikodon i nalokson
|
|
WO2010151741A1
(en)
|
2009-06-25 |
2010-12-29 |
Elite Laboratories, Inc. |
Abuse resistant oral dosage forms
|
|
NZ703564A
(en)
|
2010-03-11 |
2016-08-26 |
Wyeth Llc |
Oral formulations and lipophilic salts of methylnaltrexone
|
|
WO2011141488A2
(en)
*
|
2010-05-10 |
2011-11-17 |
Euro-Celtique S.A. |
Pharmaceutical compositions comprising hydromorphone and naloxone
|
|
NZ603173A
(en)
|
2010-05-10 |
2014-10-31 |
Euro Celtique Sa |
Manufacturing of active-free granules and tablets comprising the same
|
|
CN103002881B
(zh)
|
2010-05-10 |
2015-09-02 |
欧洲凯尔特公司 |
载有活性剂的颗粒与额外活性剂的组合
|
|
JP2016525138A
(ja)
|
2013-07-23 |
2016-08-22 |
ユーロ−セルティーク エス．エイ． |
疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
|
|
AU2014306759B2
(en)
|
2013-08-12 |
2018-04-26 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded immediate release abuse deterrent pill
|
|
WO2015071380A1
(en)
|
2013-11-13 |
2015-05-21 |
Euro-Celtique S.A. |
Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
|
|
US10105360B2
(en)
|
2013-12-11 |
2018-10-23 |
Develco Pharma Schweiz Ag |
Method and composition for the treatment of opioid induced constipation
|
|
EP3079661B1
(de)
|
2013-12-11 |
2021-05-05 |
Algobate AG |
Naloxon-monopräparat und mehrschichttablette
|
|
US10172797B2
(en)
|
2013-12-17 |
2019-01-08 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
|
US9492444B2
(en)
|
2013-12-17 |
2016-11-15 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
|
DK3169315T3
(da)
|
2014-07-17 |
2020-08-10 |
Pharmaceutical Manufacturing Res Services In |
Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
|
|
US9132096B1
(en)
|
2014-09-12 |
2015-09-15 |
Alkermes Pharma Ireland Limited |
Abuse resistant pharmaceutical compositions
|
|
JP6686013B2
(ja)
|
2014-10-17 |
2020-04-22 |
サリックス ファーマスーティカルズ，インコーポレーテッド |
腫瘍の進行を減弱させるためのメチルナルトレキソンの使用
|
|
WO2016064873A1
(en)
|
2014-10-20 |
2016-04-28 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extended release abuse deterrent liquid fill dosage form
|
|
US20160256452A1
(en)
*
|
2015-03-06 |
2016-09-08 |
Develco Pharma Schweiz Ag |
Composition Of Opioid Receptor Antagonists For Use In Treatment Of Constipation With Highly Increased Whole Gut Transit Time
|
|
US20160256451A1
(en)
*
|
2015-03-06 |
2016-09-08 |
Develco Pharma Schweiz Ag |
Dosage of naloxone
|
|
WO2016193456A2
(en)
|
2015-06-03 |
2016-12-08 |
Develco Pharma Schweiz Ag |
Opioid receptor antagonist for use in treating patients with severe constipation
|
|
EP3290027A1
(en)
|
2016-09-02 |
2018-03-07 |
Develco Pharma Schweiz AG |
Method and composition for the treatment of opioid induced constipation
|
|
BR112021022194A2
(pt)
|
2019-05-07 |
2021-12-28 |
Bausch Health Ireland Ltd |
Formulações líquidas para dosagem oral de metilnaltrexona
|